Loading…
Actuate Therapeutics, Inc. Common stock is projected to rise to $2.63 by 2027, a +25% move from its current price of $2.11. ACTU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.00 | $2.11 | $2.23 | +0.13% |
| May 30 | $1.96 | $2.12 | $2.29 | +0.27% |
| May 31 | $1.92 | $2.12 | $2.33 | +0.40% |
| Jun 1 | $1.90 | $2.12 | $2.37 | +0.54% |
| Jun 2 | $1.88 | $2.12 | $2.40 | +0.67% |
| Jun 3 | $1.86 | $2.13 | $2.44 | +0.81% |
| Jun 4 | $1.84 | $2.13 | $2.47 | +0.94% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.84 | $2.13 | $2.47 | +0.94% |
| Week 2 | $1.75 | $2.15 | $2.64 | +1.89% |
| Week 3 | $1.68 | $2.17 | $2.80 | +2.85% |
| Week 4 | $1.63 | $2.19 | $2.94 | +3.82% |
| Week 5 | $1.59 | $2.21 | $3.07 | +4.80% |
| Week 6 | $1.56 | $2.23 | $3.20 | +5.78% |
| Week 7 | $1.53 | $2.25 | $3.32 | +6.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on cancer therapies in the United States. Its lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.
Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Actuate Therapeutics, Inc. Common stock is currently priced at $2.11. It has a market cap of $50.48M and ranks 4537 by market capitalization.
The asset sits in the Healthcare sector and presently trades around the $2 level. The latest forecast path shows the average price hovering near the current level in 2026 and then moving higher in the following years, with meaningful upside into the late 2020s and beyond.
Forecasts indicate the average price advancing from $2.11 in 2026 to $2.63 in 2027, and reaching higher levels in 2033–2050, with 2033 avg $3.17, 2034 avg $3.28, 2040 avg $4.56, and 2050 avg $5.16. Corresponding ROIs rise to 24.9% in 2027 and to the high teens and beyond later in the horizon, ending at 144.5% in 2050, though there are also years of negative or modest returns such as -7.6% in 2031.
A major floor 38.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 58.3% above — a clean break opens room to run.
A major ceiling 177.7% above — clearing it would confirm fresh momentum.
Key ACTU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACTU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.32 | Sell | $2.29 | Sell |
| MA 10 | $2.49 | Sell | $2.45 | Sell |
| MA 20 | $2.76 | Sell | $2.58 | Sell |
| MA 50 | $2.52 | Sell | $2.82 | Sell |
| MA 100 | $3.52 | Sell | $3.55 | Sell |
| MA 200 | $5.34 | Sell | $4.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.73 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -143.37 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -36.06 | Sell |
| Bollinger %B (20,2) | 0.02 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 23.56 | Buy |
| Momentum (10) | -0.78 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 2.18 | Sell |
| ADX (14) | 17.77 | Neutral |
| ATR (14) | 0.14 | Info |
Bearish sentiment dominates in the near term. The RSI(14) is 40. The 50-day simple moving average is $2.52, while the 200-day simple moving average is $5.34.
Near-term support is at $2.11 and resistance at $3.34. The 30-day price range spans from $1.46 to $3.04, and annualized volatility stands at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.72 | $2.11 | $3.22 | 0% | Neutral | |
| $1.90 | $2.63 | $3.96 | +25% | Bullish | |
| $1.63 | $2.40 | $3.83 | +14% | Neutral | |
| $1.49 | $2.31 | $3.87 | +9% | Neutral | |
| $1.35 | $2.19 | $3.83 | +4% | Neutral | |
| $1.15 | $1.95 | $3.52 | -8% | Neutral | |
| $1.42 | $2.52 | $4.69 | +20% | Neutral | |
| $1.72 | $3.17 | $6.06 | +50% | Bullish | |
| $1.71 | $3.28 | $6.42 | +55% | Bullish | |
| $1.51 | $3.02 | $6.04 | +43% | Bullish | |
| $2.05 | $4.56 | $10.03 | +116% | Bullish | |
| $2.32 | $5.16 | $11.87 | +145% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.72 | $2.11 | $2.50 | +0.00% |
| June 2026 | $1.86 | $2.23 | $2.77 | +5.70% |
| July 2026 | $1.95 | $2.38 | $3.04 | +6.89% |
| August 2026 | $1.90 | $2.35 | $3.05 | -1.56% |
| September 2026 | $1.89 | $2.36 | $3.12 | +0.61% |
| October 2026 | $2.00 | $2.52 | $3.37 | +6.72% |
| November 2026 | $1.97 | $2.52 | $3.41 | -0.14% |
| December 2026 | $1.83 | $2.35 | $3.22 | -6.46% |
Click any year to see its month-by-month ACTU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Actuate Therapeutics, Inc. Common stock's 2026 outlook centres on $2.11, within a $1.72 to $3.22 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACTU could reach as high as $3.96, with a base case around $2.63 and support toward $1.90 — roughly +25% from $2.11. Buyers look set to stay in control over this stretch.
Expect ACTU to range from $1.63 to $3.83 through 2028. The $2.40 average target implies a +14% move from current prices. That is -9% versus the projected 2027 average. Price action looks broadly range-bound.
The ACTU price prediction for 2029 points to an average of $2.31 (low $1.49, high $3.87) — a potential gain of +9% on today's $2.11. A consolidation phase looks the most probable path here.
In 2030, ACTU is projected to trade between $1.35 and $3.83, averaging $2.19 — a potential gain of +4% from today's $2.11. That is -5% versus the projected 2029 average. Price action looks broadly range-bound.
Actuate Therapeutics, Inc. Common stock's 2031 outlook centres on $1.95, within a $1.15 to $3.52 range. That is -11% versus the projected 2030 average. That marks a -8% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ACTU could reach as high as $4.69, with a base case around $2.52 and support toward $1.42 — roughly +20% from $2.11. Price action looks broadly range-bound.
Expect ACTU to range from $1.72 to $6.06 through 2033. The $3.17 average target implies a +50% move from current prices. That is up +26% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACTU price prediction for 2034 points to an average of $3.28 (low $1.71, high $6.42) — a potential gain of +55% on today's $2.11. Momentum favours further upside here.
In 2035, ACTU is projected to trade between $1.51 and $6.04, averaging $3.02 — a potential gain of +43% from today's $2.11. That is -8% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Actuate Therapeutics, Inc. Common stock's 2040 outlook centres on $4.56, within a $2.05 to $10.03 range. That is up +51% on the projected 2035 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2050, ACTU could reach as high as $11.87, with a base case around $5.16 and support toward $2.32 — roughly +145% from $2.11. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACTU today (≈ 473.933649 ACTU) could be worth
$2,445.4
+$1,445.4 (+145%) by 2050 · US Dollar
Based on the average projected ACTU price of $5.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACTUwould be worth at today's price.
$1,000 invested in ACTU on May 27, 2025 (≈ 96.993207 ACTU) would be worth
$204.66
-$795.34 (-79.5%) today · 0.20× · US Dollar
Based on a ACTU entry price of $10.31 vs. today's $2.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.51 | $840.64 | -15.9% |
| 1 month ago | $2.85 | $740.35 | -26.0% |
| 3 months ago | $3.95 | $534.18 | -46.6% |
| 6 months ago | $7.63 | $276.54 | -72.3% |
| 1 year ago | $10.31 | $204.66 | -79.5% |
| All time (1.8y) ago | $8.61 | $245.06 | -75.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACTU forecast.
Our base-case forecast reaches $4.20 around 2040.
Implied market cap at $4.20: $100.49M
Looking across the multi-year forecast, Actuate Therapeutics shows a path of gradual upside with several turning points. In 2027 the average price is $2.63 with a 24.9% ROI and bullish sentiment, signaling a firmer near-term trajectory.
The years 2033–2035 show notable upside: 2033 avg $3.17 with 50.3% ROI (bullish), 2034 avg $3.28 with 55.4% ROI (bullish), and 2035 avg $3.02 with 43% ROI (bullish). These years reflect a stronger price trajectory than the early horizon.
The long horizon strengthens further: 2040 avg $4.56 with 116.2% ROI (bullish) and 2050 avg $5.16 with 144.5% ROI (bullish). There is a downside year in 2031 with -7.6% ROI, illustrating that the path includes risk alongside potential upside.
Tap a question to reveal the answer.
Min $1.35, Avg $2.19, Max $3.83; ROI 4%; Sentiment NEUTRAL.
The forecast shows positive ROI in several years (2027 24.9%, 2028 13.6%, 2029 9.4%, 2032 19.5%, 2033 50.3%, 2034 55.4%, 2040 116.2%, 2050 144.5%), with near-term risk including 2031 -7.6% ROI and 2026 0% ROI; sentiment ranges from NEUTRAL to BULLISH across periods.
2033 max $6.06; 2034 max $6.42, indicating possible upside near that level in those years per forecasts.
Current price $2.11; market cap $50.48M.
Low $1.46, High $3.04.
Actuate Therapeutics, Inc. Common stock Community Discussion
0Share your Actuate Therapeutics, Inc. Common stock price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.